Levosalbutamol (Levalbuterol) Syrup Dosage for Bronchospasm
The recommended dosage of Levosalbutamol (Levalbuterol) syrup for treating bronchospasm is 0.31 mg/3 mL for children under 5 years, 0.31-1.25 mg in 3 mL for children 5-11 years, and 0.63-1.25 mg for adults. 1, 2
Dosage by Age Group
- Children under 5 years: 0.31 mg/3 mL via nebulizer solution 1
- Children 5-11 years: 0.31-1.25 mg in 3 mL via nebulizer solution 1, 2
- Adults: 0.63-1.25 mg via nebulizer solution 1, 2
Administration Guidelines
- Levosalbutamol is the R-isomer of albuterol and provides bronchodilation at approximately half the dose of racemic albuterol 2, 3
- For severe exacerbations, dosage may be increased, similar to albuterol dosing protocols 1
- Levosalbutamol syrup can be administered via nebulizer for optimal delivery 2
- The medication is compatible with budesonide inhalant suspension 1
- For sterile-filled preservative-free unit dose vials, no additional preparation is needed 1
Clinical Efficacy
- Levosalbutamol produces comparable bronchodilator response to racemic salbutamol at half the dose 4
- The medication is effective for treating bronchospasm in both adults and children with asthma and COPD 3, 5
- Levosalbutamol has been shown to be effective in managing acute and chronic cough due to allergic conditions, bronchial asthma, and COPD 6
Advantages Over Racemic Albuterol
- Levosalbutamol contains only the therapeutically active R-isomer, avoiding potential adverse effects of the S-isomer 3
- Preclinical studies suggest the S-isomer may oppose the beneficial effects of the R-isomer 3, 5
- May provide comparable bronchodilation with potentially reduced beta-mediated adverse effects 3
Monitoring and Safety
- Common side effects include tremor (1%), palpitation (0.9%), and vomiting (0.7%) 6
- Side effects are typically mild and transient, rarely requiring treatment discontinuation 6
- As with other beta-agonists, monitor for tachycardia, skeletal muscle tremor, hypokalemia, and hyperglycemia 2
- Increasing use or lack of expected effect indicates diminishing asthma control 2
Special Considerations
- For children under 6 years, Levosalbutamol does not have FDA-approved labeling, but clinical data supports its use 1
- For delivery via metered-dose inhaler with a valved holding chamber, performance is comparable whether using charge-dissipative materials or conventional polymers that have been prewashed 7
- Regular use exceeding twice weekly for symptom control indicates poor asthma control and need for controller medication adjustment 2